---
title: "康哲药业单抗注射液「MG-K10」上市申请获受理"
description: "康哲药业公布，旗下德镁医药连同其附属拥有共同开发权和独家商业化权利的 1 类新药抗 IL-4Rα MG-K10 人源化单抗注射液 (通用名︰柯美奇拜单抗注射液，「MG-K10」) 中国上市许可申请获中国国家药品监督管理局受理。「MG-K10」拟用于治疗外用药控制不佳或不适用外用药治疗的成人中重度特应性皮炎。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263529522.md"
published_at: "2025-10-30T13:12:19.000Z"
---

# 康哲药业单抗注射液「MG-K10」上市申请获受理

> 康哲药业公布，旗下德镁医药连同其附属拥有共同开发权和独家商业化权利的 1 类新药抗 IL-4Rα MG-K10 人源化单抗注射液 (通用名︰柯美奇拜单抗注射液，「MG-K10」) 中国上市许可申请获中国国家药品监督管理局受理。「MG-K10」拟用于治疗外用药控制不佳或不适用外用药治疗的成人中重度特应性皮炎。

康哲药业 (00867.HK) 公布，旗下德镁医药连同其附属拥有共同开发权和独家商业化权利的 1 类新药抗 IL-4Rα MG-K10 人源化单抗注射液 (通用名︰柯美奇拜单抗注射液，「MG-K10」) 中国上市许可申请获中国国家药品监督管理局受理。

「MG-K10」拟用於治疗外用药控制不佳或不适用外用药治疗的成人中重度特应性皮炎。

### Related Stocks

- [00867.HK - 康哲药业](https://longbridge.com/zh-CN/quote/00867.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insilico and CMS launch drug discovery collaborations for CNS diseases | Insilico Medicine has partnered with China Medical System (CMS) to launch AI drug discovery collaborations targeting cen | [Link](https://longbridge.com/zh-CN/news/275583451.md) |
| JSW MG Motor India Unveils MG MAJESTOR, D+ Segment SUV | JSW MG MOTOR INDIA UNVEILS MG MAJESTOR, D+ SEGMENT SUV | [Link](https://longbridge.com/zh-CN/news/275738598.md) |
| Restoring economic growth in Lebanon will require comprehensive reforms, IMF says | WASHINGTON, Feb 19 (Reuters) - Lebanon’s economy has shown resilience despite conflicts in the region, with tourism fuel | [Link](https://longbridge.com/zh-CN/news/276355421.md) |
| Sk Innovation Selected As Developer Of $2.3 Billion LNG Power Project In Vietnam | SK Innovation Co Ltd :SK INNOVATION: SELECTED AS DEVELOPER OF $2.3 BILLION LNG POWER PROJECT IN VIETNAM | [Link](https://longbridge.com/zh-CN/news/276292221.md) |
| 11:30 ETInventHelp Inventors Develop New Vaporizer and Attachment (PTA-448) | InventHelp has announced the development of a new vaporizer and attachment called the SPLIF T, designed to allow users t | [Link](https://longbridge.com/zh-CN/news/276357553.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。